The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1693-1707

  Podar, Klaus ^a   Raab, Marc S ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Activators; Inhibitors; Protein kinase C; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; BORTEZOMIB; BRYOSTATIN 1; CARBOPLATIN; CISPLATIN; CURCUMIN; CYTARABINE; DEHYDRODIDEMNIN B; DEXAMETHASONE; ENZASTAURIN; FLUDARABINE; GEMCITABINE; ISIS 3521; LENALIDOMIDE; LY 9000003; MELPHALAN; MIDOSTAURIN; PACLITAXEL; PEP 005; PEPLIN; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; RESVERATROL; RETINOL; RITUXIMAB; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ISOENZYME;

ABNORMAL URINE COMPOSITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; FATIGUE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE; TUMOR GROWTH; VOMITING; ANIMAL; BLOOD DISEASE; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; HEMATOLOGIC NEOPLASMS; HUMANS; ISOENZYMES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN KINASE C;

EID: 35248870218     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1693     Document Type: Article

References (194)

1. BERENBLUM I: The mechnism of carcinogenesis: a study of the significance of carcinogenic action and related phenomena. Cancer Res. (1941) 1(1):807-814.
2. CASTAGNA M, TAKAI Y, KAIBUCHI K et al.: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. (1982) 257(13):7847-7851.
3. LEACH KL, JAMES ML, BLUMBERG PM: Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc. Natl. Acad. Sci. USA (1983) 80(14):4208-4212.
4. NISHIZUKA Y: The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature (1984) 308(5961):693-698.
5. NISHIZUKA Y: Discovery and prospect of protein kinase C research: epilogue. J. Biochem. (Tokyo) (2003) 133(2):155-158.
6. SHARKEY NA, LEACH KL, BLUMBERG PM: Competitive inhibition by diacylglycerol of specific phorbol ester binding. Proc. Natl. Acad. Sci. USA (1984) 81(2):607-610.
7. GRINER EM, KAZANIETZ MG: Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer (2007) 7(4):281-294.
8. MACKAY HJ, TWELVES CJ: Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer (2007) 7(7):554-562.
9. NISHIZUKA Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. (1995) 9(7):484-496.
10. TSUTAKAWA SE, MEDZIHRADSZKY KF, FLINT AJ, BURLINGAME AL, KOSHLAND DE Jr: Determination of in vivo phosphorylation sites in protein kinase C. J. Biol. Chem. (1995) 270(45):26807-26812.
11. KERANEN LM, DUTIL EM, NEWTON AC: Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr. Biol. (1995) 5(12):1394-1403.
12. BORNANCIN F, PARKER PJ: Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase C-α. Curr. Biol. (1996) 6(9):1114-1123.
13. BORNANCIN F, PARKER PJ: Phosphorylation of protein kinase C-α on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state. J. Biol. Chem. (1997) 272(6):3544-3549.
14. LE GOOD JA, ZIEGLER WH, PAREKH DB et al.: Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science (1998) 281(5385):2042-2045.
15. BEHN-KRAPPA A, NEWTON AC: The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr. Biol. (1999) 9(14):728-737.
16. IGLESIAS T, WALDRON RT, ROZENGURT E: Identification of in vivo phosphorylation sites required for protein kinase D activation. J. Biol. Chem. (1998) 273(42):27662-27667.
17. JOHANNES FJ, PRESTLE J, EIS S, OBERHAGEMANN P, PFIZENMAIER K: PKC-μ is a novel, atypical member of the protein kinase C family. J. Biol. Chem. (1994) 269(8):6140-6148.
18. MATTHEWS SA, ROZENGURT E, CANTRELL D: Characterization of serin 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase C-μ. J. Biol. Chem. (1999) 274(37):26543-26549.
19. VALVERDE AM, SINNETT-SMITH J, VAN LINT J, ROZENGURT E: Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc. Natl. Acad. Sci. USA (1994) 91(18):8572-8576.
20. BLACKSHEAR PJ: The MARCKS family of cellular protein kinase C substrates. J. Biol. Chem. (1993) 268(3):1501-1504.
21. MOCHLY-ROSEN D: Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science (1995) 268(5208):247-251.
22. CSUKAI M, MOCHLY-ROSEN D: Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol. Res. (1999) 39(4):253-259.
23. WAY KJ, CHOU E, KING GL: Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol. Sci. (2000) 21(5):181-187.
24. NISHIZUKA Y: Studies and perspectives of protein kinase C. Science (1986) 233(4761):305-312.
25. NISHIZUKA Y: The Albert Lasker medical awards. The family of protein kinase C for signal transduction. JAMA (1989) 262(13):1826-1833.
26. ASAOKA Y, NAKAMURA S, YOSHIDA K, NISHIZUKA Y: Protein kinase C, calcium and phospholipid degradation. Trends Biochem. Sci. (1992) 17(10):414-417.
27. DEKKER LV, PARKER PJ: Protein kinase C - a question of specificity. Trends Biochem. Sci. (1994) 19(2):73-77.
28. NEWTON AC: Protein kinase C: structure, function, and regulation. J. Biol. Chem. (1995) 270(48):28495-28498.
29. NEWTON AC: Regulation of protein kinase C. Curr. Opin. Cell Biol. (1997) 9(2):161-167.
30. BLACK JD: Protein kinase C-mediated regulation of the cell cycle. Front Biosci. (2000) 5:D406-D423.
31. O'BRIAN C. VOGEL VG, SINGLETARY SE, WARD NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. (1989) 49(12):3215-3217.
32. TAKENAGA K, TAKAHASHI K: Effects of 12-O-tetradecanoylphorbol-13-acetate on adhesiveness and lung-colonizing ability of Lewis lung carcinoma cells. Cancer Res. (1986) 46(1):375-380.
33. SCHWARTZ GK, JIANG J, KELSEN D, ALBINO AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J. Natl. Cancer Inst. (1993) 85(5):402-407.
34. GOKMEN-POLAR Y, MURRAY NR, VELASCO MA, GATALICA Z, FIELDS AP: Elevated protein kinase C-βII is an early promotive event in colon carcinogenesis. Cancer Res. (2001) 61(4):1375-1381.
35. DA ROCHA AB, MANS DR, REGNER A, SCHWARTSMANN G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 7(1):17-33.
36. DEAN N, MCKAY R, MIRAGLIA L et al.: Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res. (1996) 56(15):3499-3507.
37. SHIPP MA, ROSS KN, TAMAYO P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 8(1):68-74.
38. HANS CP, WEISENBURGER DD, GREINER TC et al.: Expression of PKC-β or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. (2005) 18(10):1377-1384.
39. FELLI MP, VACCA A, CALCE A et al.: PKC-θ mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene (2005) 24(6):992-1000.
40. GORELIK G, BARREIRO ARCOS ML, KLECHA AJ, CREMASCHI GA: Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line. Biochim. Biophys. Acta (2002) 1588(2):179-188.
41. VILLALBA M, KASIBHATLA S, GENESTIER. L et al.: Protein kinase C-θ cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. J. Immunol. (1999) 163(11):5813-5819.
42. PARANT MR, KLEIN B, VIAL H: Abnormal behavior of Protein kinase C in the human myeloma cell line, RPMI 8226. FEBS Lett. (1990) 269(2):331-335.
43. NI H, ERGIN M, TIBUDAN SS et al.: Protein kinase C-δ is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis. Br. J. Haematol. (2003) 121(6):849-856.
44. THABARD W, COLLETTE M, BATAILLE R, AMIOT M: Protein kinase C-δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells. Biochem. J. (2001) 358(Part 1):193-200.
45. PODAR K, TAI YT, LIN BK et al.: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinasc-dependent PKC-α activation. J. Biol. Chem. (2002) 277(10):7875-7881.
46. QIANG YW, WALSH K. YAO L et al.: Wnts induce migration and invasion of myeloma plasma cells. Blood (2005) 106(5):1786-1793.
47. CHAUHAN D, PANDEY P, OGATA A et al.: Cytochrome C-dependent and -independent induction of apoptosis in multiple myeloma cells. J. Biol. Chem. (1997) 272(48):29995-29997.
48. PODAR K, ANDERSON KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood (2005) 105(4):1383-1395.
49. BERGSAGEL PL, KUEHL WM, ZRAN F et al.: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 106(1):296-303.
50. DRING AM, DAVIES FE, FENTON JA et al.: A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin. Cancer Res. (2004) 10(17):5692-5701.
51. PODAR K, RAAB MS, ZHANG J et al.: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood (2007) 109(4):1669-1677.
52. MICHIE AM, NAKAGAWA R. The link between PKC-α regulation and cellular transformation. Immunol. Lett. (2005) 96(2):155-162.
53. FREY MR, SAXON ML, ZHAO X et al.: Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21 (waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J. Biol. Chem. (1997) 272(14):9424-9435.
54. DETJEN KM, BREMBECK FH, WELZEL M et al.: Activation of protein kinase C-α inhibits growth of pancreatic cancer cells via p21 (cip)-mediated G(1) arrest. J. Cell Sci. (2000) 113(Part 17):3025-3035.
55. SLOSBERG ED, KLEIN MG, YAO Y et al.: The α isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21cip1 induction in HC11 mammary epithelial cells. Oncogene (1999) 18(48):6658-6666.
56. OSTER H, LEITGES M: Protein kinase C-α but not PKC-ζ suppresses intestinal tumor formation in ApcMin/+ mice. Cancer Res. (2006) 66(14):6955-6963.
57. KOLCH W, HEIDECKER G, KOCHS G et al.: Protein kinase C-α activates RAF-1 by direct phosphorylation. Nature (1993) 364(6434):249-252.
58. RUVOLO PP, DENG X, CARR BK, MAY WS: A functional role for mitochondrial protein kinase C-α in Bcl2 phosphorylation and suppression of apoptosis. J. Biol Chem. (1998) 273(39):25436-25442.
59. WANG XY, REPASKY E, LIU HT: Antisense inhibition of protein kinase C-α reverses the transformed phenotype in human lung carcinoma cells. Exp. Cell Res. (1999) 250(1):253-263.
60. AHMAD S, GLAZER RI: Expression of the antisense cDNA for protein kinase C-α attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol. (1993) 43(6):858-862.
61. OKUDA H, ADACHI M, MIYAZAWA M, HINODA Y, IMAI K: Protein kinase C-α promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage. Oncogene (1999) 18(40):5604-5609.
62. WAYS DK, KUKOLY CA, DEVENTE J et al.: MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. (1995) 95(4):1906-1915.
63. MANDIL R, ASHKENAZI E, BLASS M et al.: Protein kinase C-α and protein kinase C-δ play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. (2001) 61(11):4612-4619.
64. BESSON A, YONG VW: Involvement of p21(Waf1/Cip1) in protein kinase C-α-induced cell cycle progression. Mol. Cell. Biol. (2000) 20(13):4580-4590.
65. MURRAY NR, BAUMGARDNER GP, BURNS DJ, FIELDS AP: Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that βII protein kinase C is required for proliferation. J. Biol. Chem. (1993) 268(21):15847-15853.
66. NAKAGAWA R, SOH JW, MICHIE AM: Subversion of protein kinase C-α signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. (2006) 66(1):527-534.
67. SHIMIZU Y, VAN SEVENTER GA, ENNIS E et al.: Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. J. Exp. Med. (1992) 175(2):577-582.
68. SHATTIL SJ, HAIMOVICH B, CUNNINGHAM M et al.: Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors. J. Biol. Chem. (1994) 269(20):14738-14745.
69. NG T. SHIMA D, SQUIRE A et al.: PKC-α regulates β1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J. (1999) 18(14):3909-3923.
70. NG T, PARSONS M, HUGHES WE et al.: Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. (2001) 20(11):2723-2741.
71. PARSONS M, KEPPLER MD, KLINE A et al.: Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol. Cell. Biol. (2002) 22(16):5897-5911.
72. TAN M, LI P, SUN M, YIN G, YU D: Upregulation and activation of PKC-α by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC-α and Src inhibitors. Oncogene (2006) 25(23):3286-3295.
73. PODAR K, TAI YT, DAVIES FE et al.: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood (2001) 98(2):428-435.
74. SU TT, GUO B, KAWAKAMI Y et al.: PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat. Immunol. (2002) 3(8):780-786.
75. SAIJO K, MECKLENBRAUKER I, SANTANA A et al.: Protein kinase C-β controls NF-κB activation in B cells through selective regulation of the IκB kinase α. J. Exp. Med. (2002) 195(12):1647-1652.
76. SHINOHARA H, YASUDA T, AIBA Y et al.: PKC-β regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J. Exp. Med. (2005) 202(10):1423-1431.
77. HOUSEY GM, JOHNSON MD, HSIAO WL et al.: Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell (1988) 52(3):343-354.
78. CHOI PM, TCHOU-WONG KM, WEINSTEIN IB: Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol. Cell. Biol. (1990) 10(9):4650-4657.
79. GAMARD CJ, BLOBE GC, HANNUN YA, OBEID LM: Specific role for protein kinase C-β in cell differentiation. Cell Growth Differ. (1994) 5(4):405-409.
80. XIA P, AIELLO LP, ISHII H et al.: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98(9):2018-2026.
81. TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18(13):2221-2230.
82. YOSHIJI H, KURIYAMA S, WAYS DK et al.: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. (1999) 59(17):4413-4418.
83. SUZUMA K, TAKAHARA N, SUZUMA I et al.: Characterization of protein kinase C-β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl. Acad. Sci. USA (2002) 99(2):721-726.
84. WONG C, JIN ZG: Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J. Biol. Chem. (2005) 280(39):33262-33269.
85. TAYLOR CJ, MOTAMED K, LILLY B: Protein kinase C and downstream signaling pathways in a three-dimensional model of phorbol ester-induced angiogenesis. Angiogenesis (2006) 9(2):39-51.
86. SLEDGE GW Jr, GOKMEN-POLAR Y: Protein kinase C-β as a therapeutic target in breast cancer. Semin. Oncol. (2006) 33(3 Suppl. 9):S15-S18.
87. TEICHER BA, MENON K, ALVAREZ E et al.: Antiangiogenic and antitumor effects of a protein kinase C-α inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo (Athens, Greece) (2001) 15(3):185-193.
88. MOREAU AS, JIA X, NGO HT et al.: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom's macroglobulinemia. Blood (2007).
89. JACKSON DN, FOSTER DA: The enigmatic protein kinase C-δ: complex roles in cell proliferation and survival. FASEB J. (2004) 18(6):627-636.
90. EMOTO Y, MANOME Y, MEINHARDT G et al.: Proteolytic activation of protein kinase C-δ by an ICE-like protease in apoptotic cells. EMBO J. (1995) 14(24):6148-6156.
91. GHAYUR T, HUGUNIN M, TALANIAN RV et al.: Proteolytic activation of protein kinase C-δ by an ICE/CED 3-like protease induces characteristics of apoptosis. J. Exp. Med. (1996) 184(6):2399-2404.
92. BHARTI A, KRAEFT SK, GOUNDER M et al.: Inactivation of DNA-dependent protein kinase by protein kinase C-δ: implications for apoptosis. Mol. Cell. Biol. (1998) 18(11):6719-6728.
93. YUAN ZM, UTSUGISAWA T, ISHIKO T et al.: Activation of protein kinase C-δ by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene (1998) 16(13):1643-1648.
94. CROSS T, GRIFFITHS G, DEACON E et al.: PKC-δ is an apoptotic lamin kinase. Oncogene (2000) 19(19):2331-2337.
95. FRASCH SC, HENSON PM, KAILEY JM et al.: Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase C-δ. J. Biol. Chem. (2000) 275(30):23065-23073.
96. EMOTO Y, KISAKI H, MANOME Y, KHARBANDA S, KUFE D: Activation of protein kinase C-δ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood (1996) 87(5):1990-1996.
97. DENNING MF, WANG Y, NICKOLOFF BJ, WRONE-SMITH T: Protein kinase C-δ is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J. Biol. Chem. (1998) 273(45):29995-30002.
98. REYLAND ME, ANDERSON SM, MATASSA AA, BARZEN KA, QUISSELL DO: Protein kinase C-δ is essential for etoposide-induced apoptosis in salivary gland acinar cells. J. Biol. Chem. (1999) 274(27):19115-19123.
99. PERSAUD SD, HOANG V, HUANG J, BASU A: Involvement of proteolytic activation of PKCδ in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. Int. J. Oncol. (2005) 27(1):149-154.
100. HUMPHRIES MJ, LIMESAND KH, SCHNEIDER JC et al.: Suppression of apoptosis in the protein kinase C-δ null mouse in vivo. J. Biol. Chem. (2006) 281(14):9728-9737.
101. NAKAGAWA M, OLIVA JL, KOTHAPALLI D et al.: Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase C-δ-dependent induction of p21. J. Biol. Chem. (2005) 280(40):33926-33934.
102. ASHTON AW, WATANABE G, ALBANESE C et al.: Protein kinase C-δ inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1). J. Biol. Chem. (1999) 274(30):20805-20811.
103. FUKUMOTO S, NISHIZAWA Y, HOSOI M et al.: Protein kinase C-δ inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J. Biol. Chem. (1997) 272(21):13816-13822.
104. MISCHAK H, GOODNIGHT JA, KOLCH W et al.: Overexpression of protein kinase C-δ and -ε in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J. Biol. Chem. (1993) 268(9):6090-6096.
105. PERLETTI GP, CONCARI P, BRUSAFERRI S et al.: Protein kinase C-ε is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene (1998) 16(25):3345-3348.
106. PERLETTI GP, MARRAS E, CONCARI P, PICCININI F, TASHJIAN AH Jr: PKC-δ acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene (1999) 18(5):1251-1256.
107. PAL S, CLAFFEY KP, DVORAK HF, MUKHOPADHYAY D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth Factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. (1997) 272(44):27509-27512.
108. DATTA K, NAMBUDRIPAD R, PAL S et al.: Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J. Biol. Chem. (2000) 275(27):20700-20706.
109. KILEY SC, CLARK KJ, DUDDY SK, WELCH DR, JAKEN S: Increased protein kinase C-δ in mammary tumor cells: relationship to transformation and metastatic progression. Oncogene (1999) 18(48):6748-6757.
110. KILEY SC, CLARK KJ, GOODNOUGH M, WELCH DR, JAKEN S: Protein kinase C-δ involvement in mammary tumor cell metastasis. Cancer Res. (1999) 59(13):3230-3238.
111. WERT MM, PALFREY HC: Divergence in the anti-apoptotic signalling pathways used by nerve growth factor and basic fibroblast growth Factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C-δ. Biochem. J. (2000) 352(Part 1):175-182.
112. RINGSHAUSEN I, SCHNELLER F, BOGNER C et al.: Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C-δ. Blood (2002) 100(10):3741-3748.
113. CLARK AS, WEST KA, BLUMBERG PM, DENNIS PA: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC-δ promotes cellular survival and chemotherapeutic resistance. Cancer Res. (2003) 63(4):780-786.
114. NABHA SM, GLAROS S, HONG M et al.: Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene (2005) 24(19):3166-3176.
115. PAN Q, BAO LW, KLEER CG et al.: Protein kinase C-ε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. (2005) 65(18):8366-8371.
116. BASU A, WEIXEL KM: Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int. J. Cancer (1995) 62(4):457-460.
117. DING L, WANG H, LANG W. XIAO L: Protein kinase C-ε promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J. Biol. Chem. (2002) 277(38):35305-35313.
118. OKHRIMENKO H, LU W, XIANG C et al.: Protein kinase C-ε regulates the apoptosis and survival of glioma cells. Cancer Res. (2005) 65(16):7301-7309.
119. LU D, HUANG J, BASU A: Protein kinase C-ε activates protein kinase B/ Akt via DNA-PK to protect against TNF-α-induced cell death. J. Biol. Chem (2006) 281(32):22799-22807.
120. CACACE AM, GUADAGNO SN, KRAUSS RS, FABBRO D, WEINSTEIN IB: The ε isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene (1993) 8(8):2095-2104.
121. BORNER C, FILIPUZZI I, WEINSTEIN IB, IMBER R: Failure of wild-type or a mutant form of protein kinase C-α to transform fibroblasts. Nature (1991) 353(6339):78-80.
122. BRENNER W, FARBER G, HERGET T et al.: Protein kinase C-η is associated with progression of renal cell carcinoma (RCC) Anticancer Res. (2003) 23(5A):4001-4006
123. BECK JF, BOHNET B, BRUGGER D et al.: Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res. (1998) 18(2A):701-705.
124. BLAY P, ASTUDILLO A, BUESA JM et al.: Protein kinase C-θ is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin. Cancer Res. (2004) 10(12 Part 1):4089-4095.
125. GRAFF JR, MCNULTY AM, HANNA KR et al.: The protein kinase C-β-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. (2005) 65(16):7462-7469.
126. CARDUCCI MA, MUSIB L, KIES MS et al.: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C-β inhibitor, in patients with advanced cancer. J. Clin. Oncol. (2006) 24(25):4092-4099.
127. GOEKJIAN PG, JIROUSEK MR, Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs (2001) 10(12):2117-2140.
128. TEICHER BA, ALVAREZ E, MENON K et al.: Antiangiogenic effects of a protein kinase C-β-selective small molecule. Cancer Chemother. Pharmacol. (2002) 49(1):69-77.
129. KEYES KA, MANN L, SHERMAN M et al.: LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. (2004) 53(2):133-140.
130. GREEN LJ, MARDER P, RAY C et al.: Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor. Clin. Cancer Res. (2006) 12(11 Part 1):3408-3415.
131. HERBST RS, THORNTON DE, KIES MS: Phase I study of LY317615, a protein kinase C-β inhibitor. Proc. ASCO (2002) 21:A82.
132. FINE HA, KIM L, ROYCE C et al.: Results from Phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J. Clin. Oncol. (2005) 23(16S):1504.
133. ROBERTSON MJ, KAHL BS, VOSE JM et al.: Phase II study of enzastaurin, a protein kinase C-β inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. (2007) 25(13):1741-1746.
134. RIZVI MA, GHIAS K, DAVIES KM et al.: Enzastaurin (LY317615), a protein kinase C-β inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Ther. (2006) 5(7):1783-1789.
135. WEISBERG E, GRIFFIN JD: Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients. Drug Resist. Updat. (2001) 4(1):22-28.
136. GROWNEY JD, CLARK JJ, ADELSPERGER J et al.: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood (2005) 106(2):721-724.
137. GANESHAGURU K, WICKREMASINGHE RG, JONES DT et al.: Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica (2002) 87(2):167-176.
138. ARMSTRONG SA, KUNG AL, MABON ME et al.: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer cell (2003) 3(2):173-183.
139. COOLS J, STOVER EH, BOULTON CI, et al.: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR-α-induced myeloproliferative disease. Cancer cell (2003) 3(5):459-469.
140. CHEN J, LEE BH, WILLIAMS IR et al.: FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene (2005) 24(56):8259-8267.
141. AICHBERGER KJ, MAYERHOFER M, GLEIXNER KV et al.: Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood (2007) 109(7):3031-3041.
142. HEMSTROM TH, JOSEPH B, SCHULTE G, LEWENSOHN R, ZHIVOTOVSKY B: PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp. Cell Res. (2005) 305(l):200-213.
143. HEMSTROM TH, SANDSTROM M, ZHIVOTOVSKY B: Inhibitors of the PI3-kinase/ Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells. Int. J. Cancer (2006) 119(5):1028-1038.
144. SHARKEY J, KHONG T, SPENCER A: PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood (2007) 109(4):1712-1719.
145. WEISBERG E, WRIGHT RD, JIANG J et al.: Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology (2006) 131(6):1734-1742.
146. BAHLIS NJ, MIAO Y, KOC ON et al.: N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk. Lymphoma (2005) 46(6):899-908.
147. CLAMP A, JAYSON GC: The clinical development of the bryostatins. Anticancer Drugs (2002) 13(7):673-683.
148. HENNINGS H, BLUMBERG PM, PETTIT GR et al.: Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (1987) 8(9):1343-1346.
149. PHILIP PA, ZONDER JA: Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug. Expert Opin. Investig. Drugs (1999) 8(12):2189-2199.
150. SMITH JB, SMITH L, PETTIT GR: Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem. Biophys. Res. Commun. (1985) 132(3):939-945.
151. STONE RM, SARIBAN E, PETTIT GR, KUFE DW: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood (1988) 72(1):208-213.
152. KRAFT AS, WILLIAM F, PETTIT GR, LILLY MB: Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. (1989) 49(5):1287-1293.
153. DREXLER HG, GIGNAC SM, JONES RA et al.: Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood (1989) 74(5):1747-1757.
154. MOHAMMAD RM, AL-KATIB A, PETTIT GR, SENSENBRENNER LL: Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk. Res. (1993) 17(1):1-8.
155. BATTLE TE, FRANK DA: STATI mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood (2003) 102(8):3016-3024.
156. VARTERASIAN ML, PEMBERTON PA, HULBURD K et al.: Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Investig. New Drugs (2001) 19(3):245-247.
157. CLAMP AR, BLACKHALL FH, VASEY P et al.: A Phase II trial of bryostatin-1 administered by weekly 24-h infusion in recurrent epithelial ovarian carcinoma. Br. J. Cancer (2003) 89(7):1152-1154.
158. SZALLASI Z, DENNING MF, SMITH CB et al.: Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. (1994) 46(5):840-850.
159. CRAGG LH, ANDREEFF M, FELDMAN E et al.: Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clin. Cancer Res. (2002) 8(7):2123-2133.
160. JAYSON GC, CROWTHER D, PRENDIVILLE J et al.: A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 h intravenous infusion. Br. J. Cancer (1995) 72(2):461-468.
161. VARTERASIAN ML, MOHAMMAD RM, EILENDER DS et al.: Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol. (1998) 16(1):56-62.
162. VARTERASIAN ML, MOHAMMAD RM, SHURAFA MS et al.: Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. (2000) 6(3):825-828.
163. GRANT S, JARVIS WD, SWERDLOW PS et al.: Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res. (1992) 52(22):6270-6278.
164. MCGOWN AT, JAYSON G, PETTIT GR et al.: Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br. J. Cancer (1998) 77(2):216-220.
165. VRANA JA, WANG Z, RAO AS et al.: Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia (1999) 13(7):1046-1055.
166. WANG S, GUO CY, CASTILLO A, DENT P, GRANT S: Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem. Pharmacol. (1998) 56(5):635-644.
167. CHEN TC, SU S, FRY D, LIEBES L: Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer (2003) 97(9 Suppl.):2363-2373.
168. RINEHART KL: Antitumor compounds from tunicates. Med. Res. Rev. (2000) 20(1):1-27.
169. GARCIA-FERNANDEZ LF, LOSADA A, ALCAIDE V et al.: Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C-δ. Oncogene (2002) 21(49):7533-7544.
170. HORGAN K, COOKE E, HALLETT MB, MANSEL RE: Inhibition of protein kinase C mediated signal transduction by camoxifen. Importance for antitumour activity. Biochem. Pharmacol. (1986) 35(24):4463-4465.
171. GUNDIMEDAU, CHEN ZH, GOPALAKRISHNA R: Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J. Biol. Chem. (1996) 271(23):13504-13514.
172. SEROVA M, GHOUL A, BENHADJI KA et al.: Preclinical and clinical development of novel agents that target the protein kinase C family. Semin. Oncol. (2006) 33(4):466-478.
173. HENRY SP, MONTEITH D, BENNETT F, LEVIN AA: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase. Anticancer Drug Des. (1997) 12(5):409-420.
174. DEAN NM, MCKAY R, CONDON TP, BENNETT CF: Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. (1994) 269(23):16416-16424.
175. YAZAKI T, AHMAD S, CHAHLAVI A et al.: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. (1996) 50(2):236-242.
176. HANAUSKE AR, SUNDELL K, LAHN M: The role of protein kinase C-α (PKC-α) in cancer and its modulation by the novel PKC-α-specific inhibitor aprinocarsen. Curr. Pharm. Des. (2004) 10(16):1923-1936.
177. YUEN AR, HALSEY J, FISHER GA et al.: Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. (1999) 5(11):3357-3363.
178. ADVANI R, PEETHAMBARAM P, LUM BL et al.: A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C-α, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer (2004) 100(2):321-326.
179. RAO S, WATKINS D, CUNNINGHAM D et al.: Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann. Oncol. (2004) 15(9):1413-1418.
180. GROSSMAN SA, ALAVI JB, SUPKO JG et al.: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol. (2005) 7(1):32-40.
181. PAZ-ARES L, DOUILLARD JY, KORALEWSKI P et al.: Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-α antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncoll. (2006) 24(9):1428-1434.
182. KEDEI N, LUNDBERG DJ, TOTH A et al.: Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. (2004) 64(9):3243-3255.
183. HAMPSON P, CHAHAL H, KHANIM F et al.: PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the δ isoform of PKC. Blood (2005) 106(4):1362-1368.
184. OGBOURNE SM, HAMPSON P, LORD JM et al.: Proceedings of the first international conference on PEP005. Anticancer Drugs (2007) 18(3):357-362.
185. SURH YJ: Cancer chemoprevention with dietary phytochemicals. Nat. Reb. Cancer (2003) 3(10):768-780.
186. SINGH S, KHAR A: Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. (2006) 6(3):259-270.
187. SHARMA RA, STEWARD WP, GESCHER AJ: Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. (2007) 595:453-470.
188. JOE B, VIJAYKUMAR M, LOKESH BR: Biological properties of curcumin - cellular and molecular mechanisms of action. Crit. Rev. Food Sci. Nutr. (2004) 44(2):97-111.
189. MAHESHWARI RK, SINGH AK, GADDIPATI J, SRIMAL RC: Multiple biological activities of curcumin: a short review. Life Sci. (2006) 78(18):2081-2087.
190. BHARTI AC, DONATO N, AGGARWAL BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple mycloma cells. J. Immunol. (2003) 171(7):3863-3871.
191. BHARTI AC, DONATO N, SINGH S, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of NF-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood (2003) 101(3):1053-1062.
192. LIU JY, LIN SJ, LIN JK: Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradccanoyl-phorbol-13-acetate in NIH 3T3 cells. Carrinogenesis (1993) 14(5):857-861.
193. MAHMMOUD YA: Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br. J. Pharmacol. (2007) 150(2):200-208.
194. CARTER CA, KANE CJ: Therapeutic potential of natural compounds that regulate the activity of protein kinase C. Curr. Med. Chem. (2004) 11(21):2883-2902.